683 Capital Management’s Viking Therapeutics VKTX Stock Holding History

683 Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-130,000	Closed	-$4.2M	–	241
2026 Q1	$4.23M	Sell	130,000 -52,000	-29%	-$1.67M	0.22%	79
2025 Q4	$6.4M	Sell	182,000 -58,000	-24%	-$2.06M	0.28%	68
2025 Q3	$6.31M	Sell	240,000 -14,000	-6%	-$418K	0.33%	63
2025 Q2	$6.73M	Sell	254,000 -51,000	-17%	-$1.34M	0.44%	59
2025 Q1	$7.37M	Buy	305,000 +25,000	+9%	+$790K	0.51%	56
2024 Q4	$11.3M	Sell	280,000 -40,000	-13%	-$2.28M	0.7%	36
2024 Q3	$20.3M	Sell	320,000 -20,000	-6%	-$1.17M	1.54%	15
2024 Q2	$18M	Sell	340,000 -15,000	-4%	-$983K	1.36%	19
2024 Q1	$29.1M	Sell	355,000 -265,000	-43%	-$11.8M	2.13%	12
2023 Q4	$11.5M	Sell	620,000 -5,000	-0.8%	-$65.4K	0.95%	42
2023 Q3	$6.92M	Buy	625,000 +45,000	+8%	+$644K	0.54%	58
2023 Q2	$9.4M	Hold	580,000	–	–	0.68%	42
2023 Q1	$9.66M	Buy	580,000 +551,000	+1,900%	+$5.69M	0.72%	40
2022 Q4	$273K	Buy	+29,000	New	+$129K	0.02%	138

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

683 Capital Management's VKTX Position: Q2 2026 in Review

683 Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 130,000 shares — an estimated $4.2M sold.

683 Capital Management first reported a position in VKTX in Q4 2022 and held it in 14 quarters. The position peaked at $29.1M in Q1 2024. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

683 Capital Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 130,000 Viking Therapeutics shares in Q2 2026, an estimated $4.2M.
683 Capital Management first reported a position in Viking Therapeutics in Q4 2022 and held it in 14 quarters.
683 Capital Management's Viking Therapeutics position peaked at $29.1M in Q1 2024.
434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.